Provided by Tiger Trade Technology Pte. Ltd.

Biogen

217.96
-0.5450-0.25%
Volume:93.64K
Turnover:20.36M
Market Cap:32.18B
PE:38.71
High:218.63
Open:216.47
Low:213.58
Close:218.50
52wk High:222.85
52wk Low:133.53
Shares:147.64M
Float Shares:147.31M
Volume Ratio:0.74
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.71
PE(LYR):24.80

Loading ...

Wedbush Adjusts Biogen Price Target to $215 From $201, Maintains Neutral Rating

MT Newswires Live
·
Jul 30

Stifel Nicolaus Adjusts Biogen Price Target to $242 From $214

MT Newswires Live
·
Jul 30

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Dyne Therapeutics (DYN)

TIPRANKS
·
Jul 29

Biogen's Q2 Results Beat Boosted By Apellis Acquisition, Wedbush Says

MT Newswires Live
·
Jul 29

U.S. stock movers: Q2 revenue and earnings per share beat expectations, Biogen (BIIB.US) climbs over 5%

Stock News
·
Jul 29

Is Biogen (BIIB) Undervalued Following Its Q2 2026 Earnings?

Simply Wall St.
·
Jul 29

Stock Track | Biogen Soars 5% Intraday as Q2 Earnings and Revenue Beat, Growth Portfolio Drives Outlook Raise

Stock Track
·
Jul 29

Biogen Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 29

Biogen CEO Says Co Expects to be Less Intentional and More Opportunistic About M&a -Conf Call

THOMSON REUTERS
·
Jul 29

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Quest Diagnostics (DGX) and Otsuka Holdings Co (OtherOTSKF)

TIPRANKS
·
Jul 29

Old product decline offset by new launches: acquisition-driven transformation shows results, Biogen (BIIB.US) raises full-year revenue outlook

Stock News
·
Jul 29

Biogen is Maintained at Equal-Weight by Barclays

Dow Jones
·
Jul 29

Biogen Q2 Non-GAAP Earnings Fall, Revenue Rises; Lowers 2026 EPS Guidance

MT Newswires Live
·
Jul 29

Biogen - Amount of Ieepa Tariff Refunds, if Any, That We Ultimately Recover May Differ from the Full Amount We Previously Paid

THOMSON REUTERS
·
Jul 29

Biogen - Do not Expect Tariffs Currently Applicable to Our Business to Result in Material Adverse Effect on Operations in 2026 - Filing

THOMSON REUTERS
·
Jul 29

Biogen - Middle East Conflict Did not Have Any Material Effects on Our Results of Operations for Three and Six Months Ended June 30, 2026

THOMSON REUTERS
·
Jul 29

Biogen - for Apellis Integration, for Three and Six Months Ended June 30, 2026, We Recognized $153.2 Million of Net Pre-Tax Restructuring Charges

THOMSON REUTERS
·
Jul 29

Biogen - We Have not Recorded a Receivable for Any Refund of Ieepa Tariffs

THOMSON REUTERS
·
Jul 29

GUIDANCE: (BIIB) Biogen Expects 2026 Adjusted EPS Range $12.00 to $13.00, vs. FactSet Est of $12.63

MT Newswires Live
·
Jul 29

Biogen Q2 Revenue Beats Expectations on Strong Product Demand

Reuters
·
Jul 29